Positron Emission Tomography Using [18F]-Labeled Substance P Antagonist Receptor Quantifier in Finding Disease in Patients With Pancreatic Cancer
Pilot Trial of the NK1 Receptor Radio-Ligand [18F]SPA-RQ: Imaging Pancreatic Ductal Adenocarcinoma
RATIONALE: Diagnostic procedures, such as positron emission tomography (PET) using [18F]-labeled substance P antagonist receptor quantifier, may be effective in finding disease in patients with pancreatic cancer.
PURPOSE: This phase I trial is studying how well a PET scan using [18F]-labeled substance P antagonist receptor quantifier works in finding disease in patients with pancreatic cancer.
研究概览
详细说明
OBJECTIVES:
- Determine whether [18F]-labeled substance P antagonist receptor quantifier positron emission tomography can identify pancreatic cancer evident on multiphase CT scan.
OUTLINE: Patients undergo multiphase CT scan of the chest, abdomen, and pelvis. No more than 15 days later, patients receive [18F]-labeled substance P antagonist receptor quantifier IV and undergo positron emission tomography over 6 hours.
Blood is collected periodically to measure the metabolism of the radiotracer by high performance liquid chromatography with radioactive detectors.
研究类型
注册 (预期的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
Maryland
-
Bethesda、Maryland、美国、20892-1182
- Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
DISEASE CHARACTERISTICS:
Histologically confirmed adenocarcinoma of the pancreas
- Primary or metastatic disease
- At least one site of measurable disease
- Enrolled in an NCI protocol (either a treatment or screening protocol) such as NCI-05-C-0044 or NCI-05-C-0141
PATIENT CHARACTERISTICS:
Inclusion criteria:
- ECOG performance status 0-2
- WBC ≥ 1,200/mm³
- Creatinine < 2.0 mg/dL
- Negative pregnancy test
- Fertile patients must agree to use effective contraception
- Not pregnant or nursing
Exclusion criteria:
- Allergy to IV contrast
- Claustrophobia that would preclude completion of a scan or unable to lie on one's back for positron emission tomography scan
PRIOR CONCURRENT THERAPY:
Inclusion criteria:
- More than 4 weeks since prior abdominal surgery
Exclusion criteria:
- Prior participation in other research protocols within the past year such that a radiation exposure together with the present study would exceed the annual limits
- Aprepitant within 72 hours of [18F]-labeled substance P antagonist receptor quantifier positron emission tomography
学习计划
研究是如何设计的？
设计细节
- 主要用途：诊断
- 分配：非随机化
研究衡量的是什么？
主要结果指标
结果测量 |
|---|
|
Proportion of tumors detected by [18F]-labeled substance P antagonist receptor quantifier positron emission tomography
|
合作者和调查者
调查人员
- 学习椅：Richard E. Royal, MD, FACS、NCI - Surgery Branch
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.
药理学研究的临床试验
-
Hospital Clinic of BarcelonaUniversitat Politècnica de Catalunya; Institut Catala de Salut; Department of Health, Generalitat... 和其他合作者未知